Paediatric Consumer Health in Canada

PROSPECTS

Demographic trends limit development potential of paediatric consumer health

With growth in the population aged 0-12 years expected to lag behind growth in the population aged over 65 years, falling birth rates will continue to constrain the expansion of paediatric consumer health in Canada over forecast period. The negative impact of this demographic trend will be offset somewhat by immigration, which should help to ensure that growth in overall current value sales is broadly in line with that recorded over 2014-2019.

Prevalence of H1N1 flu strain boosts demand for paediatric cough/cold remedies

In any given year, the level of demand for paediatric cough, cold and allergy remedies in Canada depends on the length and severity of the annual flu and allergy seasons. In 2019, paediatric cough/cold remedies showed a modestly improved performance in volume and current value growth terms, as flu season arrived early and children and teenagers were especially susceptible to the dominant strain in circulation, H1N1.

Advice from in-store pharmacists helps to increase acceptance of private label lines

When it comes to paediatric analgesics and cough, cold and allergy remedies, most Canadian parents still favour trusted brand names such as Tylenol, Advil, Tempra and Motrin. However, it is expected that consumer acceptance of private label lines from major retail chains will increase gradually in both of these categories over the forecast period.

COMPETITIVE LANDSCAPE

Trusted brand reputations underpin continued leadership of McNeil

McNeil Consumer Healthcare maintained its overall lead in paediatric consumer health in value terms in 2019. Thanks to the trusted reputations of well-established brands such as Tylenol, Motrin, Benylin and Benadryl, the company remained the clear leader in paediatric analgesics and paediatric cough, cold and allergy remedies.

Leading players expand their offer of paediatric vitamins and dietary supplements

GSK Consumer Healthcare, the recently formed joint venture between GlaxoSmithKline Plc and Pfizer, was among the strongest performers in paediatric consumer health in 2019. As the dominant player in paediatric vitamins and dietary supplements, it remained the chief beneficiary of growing interest in such products among parents.

Child-friendly formats and competitive prices help to sustain demand for private label

Private label lines continued to perform well in paediatric consumer health in 2019, particularly in vitamins and dietary supplements. Leading retailers in Canada offer private label vitamins and dietary supplements for children in a wide array of flavours and formats.

Files are delivered directly into your account within a few minutes of purchase.